Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome

Blood

Volumn 127, Issue 21, 2016, Pages 2513-2522

  Hubbard, Nicholas ^a   Hagin, David ^a   Sommer, Karen ^a   Song, Yumei ^a   Khan, Iram ^a   Clough, Courtnee ^a   Ochs, Hans D ^a,b   Rawlings, David J ^a,b   Scharenberg, Andrew M ^a,b   Torgerson, Troy R ^a,b  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CPG OLIGODEOXYNUCLEOTIDE; GENOMIC DNA; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A2; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN M; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 7; TOLL LIKE RECEPTOR 9; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; 3' UNTRANSLATED REGION;

3' UNTRANSLATED REGION; ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CELL STIMULATION; CODING; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; ENHANCER REGION; EXON; GENE CONTROL; GENE DISRUPTION; GENE EDITING; GENE EXPRESSION; GENE LOCUS; GENE TARGETING; HOMOLOGY DIRECTED REPAIR EDITING; HUMAN; HUMAN CELL; HYPER IGM SYNDROME; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS; T LYMPHOCYTE; TRANSGENE; VIRUS RECOMBINANT; X LINKED HYPERIMMUNOGLOBULIN M SYNDROME; ANIMAL; FEMALE; GENE EXPRESSION REGULATION; GENE REARRANGEMENT; GENETICS; HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 1; IMMUNOLOGY; NONOBESE DIABETIC MOUSE; PROCEDURES; SCID MOUSE; SOMATIC HYPERMUTATION; TARGETED GENE REPAIR;

3' UNTRANSLATED REGIONS; ANIMALS; B-LYMPHOCYTES; CD40 LIGAND; ENHANCER ELEMENTS, GENETIC; FEMALE; GENE EDITING; GENE EXPRESSION REGULATION; HUMANS; HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 1; IMMUNOGLOBULIN CLASS SWITCHING; MALE; MICE; MICE, INBRED NOD; MICE, SCID; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN; T-LYMPHOCYTES; TARGETED GENE REPAIR;

EID: 85019955899     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-11-683235     Document Type: Article

References (43)

1. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67(1):2-17.
2. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229(1):152-172.
3. van Kooten C, Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol. 1997;9(3):330-337.
4. Koguchi Y, Thauland TJ, Slifka MK, Parker DC. Preformed CD40 ligand exists in secretory lysosomes in effector and memory CD4+ T cells and is quickly expressed on the cell surface in an antigen-specific manner. Blood. 2007;110(7):2520-2527.
5. Kenter AL. Class-switch recombination: after the dawn of AID. Curr Opin Immunol. 2003;15(2):190-198.
6. Crotty S. A brief history of T cell help to B cells. Nat Rev Immunol. 2015;15(3):185-189.
7. Kinoshita K, Honjo T. Linking class-switch recombination with somatic hypermutation. Nat Rev Mol Cell Biol. 2001;2(7):493-503.
8. Papavasiliou FN, Schatz DG. Somatic hypermutation of immunoglobulin genes: merging mechanisms for genetic diversity. Cell. 2002;109(suppl):S35-S44.
9. Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol. 2015;15(3):149-159.
10. Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 1994;180(4):1263-1272.
11. Karpusas M, Lucci J, Ferrant J, et al. Structure of CD40 ligand in complex with the fab fragment of a neutralizing humanized antibody. Structure. 2001;9(4):321-329.
12. Karpusas M, Hsu YM, Wang JH, et al. 2 A crystal structure of an extracellular fragment of human CD40 ligand. Structure. 1995;3(10):1031-1039.
13. Mazzei GJ, Edgerton MD, Losberger C, et al. Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem. 1995;270(13):7025-7028.
14. Graf D, Müller S, Korthäuer U, van Kooten C, Weise C, Kroczek RA. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol. 1995;25(6):1749-1754.
15. Allen RC, Armitage RJ, Conley ME, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science. 1993;259(5097):990-993.
16. Aruffo A, Farrington M, Hollenbaugh D, et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell. 1993;72(2):291-300.
17. Korthäuer U, Graf D, Mages HW, et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature. 1993;361(6412):539-541.
18. Etzioni A, Ochs HD. The hyper IgM syndrome-an evolving story. Pediatr Res. 2004;56(4):519-525.
19. Davies EG, Thrasher AJ. Update on the hyper immunoglobulin M syndromes. Br J Haematol. 2010;149(2):167-180.
20. Etzioni A, Ben-Barak A, Peron S, Durandy A. Ataxia-telangiectasia in twins presenting as autosomal recessive hyper-immunoglobulin M syndrome. Isr Med Assoc J. 2007;9(5):406-407.
21. Barry SC, Seppen J, Ramesh N, et al. Lentiviral and murine retroviral transduction of T cells for expression of human CD40 ligand. Hum Gene Ther. 2000;11(2):323-332.
22. Romero Z, Torres S, Cobo M, et al. A tissue-specific, activation-inducible, lentiviral vector regulated by human CD40L proximal promoter sequences. Gene Ther. 2011;18(4):364-371.
23. Brown MP, Topham DJ, Sangster MY, et al. Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat Med. 1998;4(11):1253-1260.
24. Tahara M, Pergolizzi RG, Kobayashi H, et al. Trans-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency. Nat Med. 2004;10(8):835-841.
25. Seyama K, Osborne WR, Ochs HD. CD40 ligand mutants responsible for X-linked hyper-IgM syndrome associate with wild type CD40 ligand. J Biol Chem. 1999;274(16):11310-11320.
26. Hollenbaugh D, Wu LH, Ochs HD, et al. The random inactivation of the X chromosome carrying the defective gene responsible for X-linked hyper IgM syndrome (X-HIM) in female carriers of HIGM1. J Clin Invest.1994;94(2):616-622.
27. Davis AJ, Chen DJ. DNA double strand break repair via non-homologous end-joining. Transl Cancer Res. 2013;2(3):130-143.
28. Certo MT, Ryu BY, Annis JE, et al. Tracking genome engineering outcome at individual DNA breakpoints. Nat Methods. 2011;8(8):671-676.
29. Taghian DG, Nickoloff JA. Chromosomal double-strand breaks induce gene conversion at high frequency in mammalian cells. Mol Cell Biol. 1997;17(11):6386-6393.
30. Voit RA, Hendel A, Pruett-Miller SM, Porteus MH. Nuclease-mediated gene editing by homologous recombination of the human globin locus. Nucleic Acids Res. 2014;42(2):1365-1378.
31. Sather BD, Romano Ibarra GS, Sommer K, et al. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med. 2015;7(307):307ra156.
32. Kim H, Kim JS. A guide to genome engineering with programmable nucleases. Nat Rev Genet. 2014;15(5):321-334.
33. Cermak T, Doyle EL, Christian M, et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 2011;39(12):e82.
34. Bandaranayake AD, Correnti C, Ryu BY, Brault M, Strong RK, Rawlings DJ. Daedalus: a robust, turnkey platform for rapid production of decigram quantities of active recombinant proteins in human cell lines using novel lentiviral vectors. Nucleic Acids Res. 2011;39(21):e143-e143.
35. Fine EJ, Cradick TJ, Zhao CL, Lin Y, Bao G. An online bioinformatics tool predicts zinc finger and TALE nuclease off-target cleavage. Nucleic Acids Res. 2014;42(6):e42.
36. Doyle EL, Booher NJ, Standage DS, et al. TAL effector-nucleotide targeter (TALE-NT) 2.0: tools for TAL effector design and target prediction. Nucleic Acids Res. 2012;40(web server issue):W117-W22.
37. Challita PM, Skelton D, el-Khoueiry A, Yu XJ, Weinberg K, Kohn DB. Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol. 1995;69(2):748-755.
38. Schumann K, Lin S, Boyer E, et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci USA. 2015;112(33):10437-10442.
39. Wang J, DeClercq JJ, Hayward SB, et al. Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. Nucleic Acids Res. 2016;44(3):e30.
40. Frock RL, Hu J, Meyers RM, Ho YJ, Kii E, Alt FW. Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat Biotechnol. 2015;33(2):179-186.
41. Fischer A, Le Deist F, Hacein-Bey-Abina S, et al. Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol Rev. 2005;203:98-109.
42. Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol. 2004;22:625-655.
43. Carbone E, Ruggiero G, Terrazzano G, et al. A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction. J Exp Med. 1997;185(12):2053-2060.